Patient Rating:

No Rating Available?

John Sweetenham, M.D., FACP, FRCP

Patient Rating:

No Rating Available?

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-6906 Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Malignant
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

John Sweetenham, MD, FRCP, FACP, is a practicing hematologist whose central clinical research interest is lymphoma and the use of stem cell transplantation. He is internationally renowned for his clinical research and has authored more than 200 original articles, chapters, and books in this area of investigation. He has been principal investigator on national and international trials in lymphoma, and is a former core committee member of the Eastern Cooperative Oncology Group Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. He also serves as Chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK.

Dr. Sweetenham has been listed in “Best Doctors in America” every year since 2003, Castle Connoly’s “America’s Top Doctors,” and “America’s Top Doctors for Cancer” every year since 2009, and has recently been acknowledged by “US News Top Doctors” and Angie’s List for Healthcare.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Academic Profile

Research Interests

  • Stem Cell Transplantation
  • Lymphomas

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Hematology/BMT
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 213-5636 Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

John Sweetenham, MD, FRCP, FACP, is executive medical director and senior director of clinical affairs at Huntsman Cancer Institute. He is also a professor of medicine in the Department of Hematology at the University of Utah and a member of the Experimental Therapeutics Program.

Dr. Sweetenham's clinical research focus is on malignant lymphomas and the use of stem cell transplantation. He has been principal investigator on national and international trials in lymphoma and is currently a core committee member of the Eastern Cooperative Oncology Group Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. He serves as chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK.

Dr. Sweetenham attended medical school at St. Bartholomew's Hospital in London, UK, and trained in oncology at the University of Southampton, UK. He has served as director of the Hematologic Malignancies and Blood and Marrow Transplant Programs at the University of Colorado; associate director for clinical research at the University of Arizona; vice chairman for clinical research at the Cleveland Clinic Taussig Cancer Institute and professor of medicine at the Cleveland Clinic Lerner College of Medicine; and medical director of the UCSD Nevada Cancer Institute.

Education

Education History

Type School Degree
Fellowship Harvard Medical School
Tumor Immunology
Visiting Fellow
Fellowship CRC Wessex Medical Oncology Unit
Oncology
Fellow
Doctoral Training University of Southampton
Medicine
Ph.D.
Research Fellow University of Southampton
Oncology
Research Fellow
Professional Medical The Medical College of St Bartholomew's Hospital
M.B.B.S.
Undergraduate St Bartholomew's Hospital Medical College, University of London
Biochemistry
B.Sc.

Publications

Selected Provider Publications

Journal Article

  1. Aronow ME, Portell CA, Sweetenham JW, Singh AD (2014). Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology, 121(1), 334-41.
  2. Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R (2014). Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol, 89(4), 349-54.
  3. Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW (2014). Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. Clin Lymphoma Myeloma Leuk, 14(3), 203-10.
  4. Deauna-Limayo D, Rajabi B, Qiu W, Htut M, Sweetenham J (2013). LETTER TO THE EDITOR: Kaposi's Sarcoma After Non-Myeloablative Hematopoietic Stem Cell Transplant: Response to Withdrawal of Immunosuppressant Therapy Correlated with Whole Blood Human Herpes Virus-8 RT-PCR levels. Leuk Lymphoma.
  5. Aronow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD (2013). Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology, 120(9), 1915-9.
  6. Aranow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD (2013). Ocular Adnexal Lymphoma: Assessment of a TNM Staging System [Epub ahead of print]. Ophthalmology, epub ahead.
  7. Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E (2012). Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia. Bone Marrow Transplant, 47(2), 231-5.
  8. Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, Dean R, Sobecks R, Andresen S, Kalaycio M (2012). Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant, 47(4), 488-93.
  9. Sweetenham JW (2012). How to treat patients with borderline DLBCL and Burkitt lymphoma. (Education Program of the European Hematology Association). Haematologica, 75-81.
  10. Sproat L, Bolwell B, Rybicki L, Dean R, Sobecks R, Pohlman B, Andresen S, Sweetenham J, Copelan E, Kalaycio M (2011). Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant, 17(7), 1079-83.
  11. Malik S, Bolwell B, Rybicki L, Copelan O, Duong H, Dean R, Sobecks R, Kalaycio M, Sweetenham J, Pohlman B, Andresen S, Tench S, Koo A, Figueroa P, Copelan E (2011). Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation. Bone Marrow Transplant, 46(12), 1519-25.
  12. Sweetenham JW (2011). "Pet negativity"--the new goal of cytoreductive therapy in Hodgkin's lymphoma? Biol Blood Marrow Transplant, 17(11), 1569-70.
  13. Sweetenham JW, Polliack A (2011). Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion? Leuk Lymphoma, 52(11), 2041-2.

Review

  1. Hill BT, Sweetenham J (2012). Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. [Review]. Leuk Lymphoma, 53(5), 763-9.
  2. Portell CA, Sweetenham JW (2012). Adult lymphoblastic lymphoma. [Review]. Cancer J, 18(5), 432-8.

Book Chapter

  1. Sweetenham JW (In Press). Hodgkin’s Disease. In Cassidy J, Bisset D, Leng M, Wagstaff J (Ed.), The Oxford Handbook of Oncology. Oxford University Press.

Clinical Trials

Video & News